^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Astrocytoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA...Adjuvant Treatment WHO grade 2, KPS ≥60....Preferred Regimens...RT + adjuvant TMZ...RT + concurrent and adjuvant TMZ....Other Recommended Regimens...TMZ
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

    Excerpt:
    ...Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will...
    Trial ID:
    NCT02510950
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Neurooncol
    Title:

    Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma

    Published date:
    09/04/2023
    Excerpt:
    TMZ-based chemoradiation is associated with survival benefit in patients with grade 2 IDH-mutant astrocytoma.
    DOI:
    https://doi.org/10.1007/s11060-023-04418-z
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    A multicenter retrospective study of timing of chemoradiation in high-risk, grade 2, IDH-mutated astrocytoma.

    Published date:
    05/25/2023
    Excerpt:
    This study sought to evaluate the clinical characteristics and survival of patients with Grade 2 IDH mutated astrocytoma treat with adjuvant temozolomide (TMZ) based chemoradiation (tRT) compared to patients treated with observation following surgery….tRT improved PFS compared to OBS (p=0.044) with mPFS 6.17y v. 3.58y.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e14035